Latest Conference Coverage

The professor of age-related diseases and Dean of the University of Exeter Medical School provided insight into the safety and efficacy of pimavanserin studied in treatment for Alzheimer psychosis.

This technology offers a non-invasive, image-guided and reversible approach to blood-brain barrier, suggesting the possibility of its use in Alzheimer disease.

The senior lecturer in Clinical Pharmacy at Aston University spoke about the findings of the ZED study, which looked into the use of hypnotic z-drugs.

ANAVEX 2-73 is being studied as the first potential precision medicine biomarker-guided, targeted therapeutic in Alzheimer disease.

The director of the University of Rochester Alzheimer's Disease Care, Research and Education Program spoke about the need to rethink trial design and Alzheimer neuropsychiatric symptom management.

BAN2401 produced a dose-dependent substantial reduction in brain amyloid plaque at the highest dose, resulting in subjects converting to amyloid negative.

This is the first large late-stage clinical trial to further support the amyloid hypothesis.

The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.

The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.

The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.

Phase III results have shown galcanezumab is efficacious for multiple headache conditions.

The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.

Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.

The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.

The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).

A non-invasive vagus nerve stimulation therapy significantly improved pain-free rates compared with a sham device for patients with episodic cluster headache and migraines.

The disease-modifying therapy showed significant improvements in 4 TSQM measures for patients with relapsing multiple sclerosis.

The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.

The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.

The announcement was discouraging to many, as only 2 agents for ALS have been granted FDA approval in as many decades.

The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

More than two-thirds of patients treated with intravenous infusions of the CGRP inhibitor eptinezumab had an average 50% reduction in migraines.

Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.

The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.

The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.